NASDAQ: BIIB · Life Sciences · 2 alerts · CIK 875045
Share price
$251.65Close, Nov 16
Market cap
$37.2B
Shares outstanding
147.82MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biogen Inc. filings on SEC EDGAR ↗
Biogen Inc. filed its Q3 2026 10-Q reporting on the quarterly period ended September 30, 2026. The filing highlights the company's strategic focus on product launches like LEQEMBI and SKYCLARYS, as well as the integration of acquisitions such as Reata, HI-Bio, and Apellis.
Biogen reported third quarter 2026 total revenue of $2.8 billion, an 11% increase year-over-year, driven by a 49% surge in its Growth Portfolio which now represents 63% of core pharmaceutical revenue. The results include the first full quarter of contribution from the acquired Apellis products and strong performance from SPINRAZA and LEQEMBI.
Term
Q3 2026
“Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products.”
Christopher A. Viehbacher, President and Chief Executive Officer
“With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders.”
Christopher A. Viehbacher, President and Chief Executive Officer